FLT3-TKD mutations associated to NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia
Outcome of patients with mutation of the FLT3 tyrosine kinase domain (FLT3-TKD) in acute myeloid leukemia (AML) remains controversial. Herein we present a retrospective study of 126 newly diagnosed AML patients performed in two French centers. FLT3-TKD mutations represented 12.7% of patients, while FLT3-internal tandem duplication (ITD) mutation was observed in 20.6% of AML cases and 1.6% of patients harbored both anomalies. At diagnosis, FLT3-TKD and FLT3-ITD were associated with higher peripheral leukocytes count and a higher blast count in bone marrow (P
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Marielle Perry, Sarah Bertoli, Cl ément Rocher, Sandrine Hayette, Sophie Ducastelle, Fiorenza Barraco, Hélène Labussière-Wallet, Gilles Salles, Christian Recher, Xavier Thomas, Etienne Paubelle Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | France Health | Hematology | Leukemia | Lymphoma | Men | Myeloma | Study